Novel frameshift variant in the IDUA gene underlies Mucopolysaccharidoses type I in a consanguineous Yemeni pedigree

Wraith, 2014, Mucopolysaccharidosis type I, Pediatr. Endocrinol. Rev., 12, 102 Vazna, 2009, Mucopolysaccharidosis type I in 21 Czech and Slovak patients: mutation analysis suggests a functional importance of C-terminus of the IDUA protein, Am. J. Med. Genet. A, 149A, 965, 10.1002/ajmg.a.32812 Lee-Chen, 2002, Mucopolysaccharidosis type I: identification and characterization of mutations affecting alpha-l-iduronidase activity, J. Formos. Med. Assoc., 101, 425 Kim, 2015, Decreased performance in IDUA knockout mouse mimic limitations of joint function and locomotion in patients with Hurler syndrome, Orphanet J. Rare Dis., 10, 121, 10.1186/s13023-015-0337-3 Chkioua, 2011, Molecular analysis of mucopolysaccharidosis type I in Tunisia: identification of novel mutation and eight Novel polymorphisms, Diagn. Pathol., 6, 39, 10.1186/1746-1596-6-39 Terlato, 2003, Can mucopolysaccharidosis type I disease severity be predicted based on a patient/'s genotype? A comprehensive review of the literature, Genet. Med., 5, 286, 10.1097/01.GIM.0000078027.83236.49 Oussoren, 2013, Residual alpha-l-iduronidase activity in fibroblasts of mild to severe mucopolysaccharidosis type I patients, Mol. Genet. Metab., 109, 377, 10.1016/j.ymgme.2013.05.016 Thomas, 2010, Childhood onset of Scheie syndrome, the attenuated form of mucopolysaccharidosis I, J. Inherit. Metab. Dis., 33, 421, 10.1007/s10545-010-9113-7 Yang, 2015, A simple and rapid method based on liquid chromatography-tandem mass spectrometry for the measurement of alpha-l-iduronidase activity in dried blood spots: an application to mucopolysaccharidosis I (Hurler) screening, Ann. Lab. Med., 35, 41, 10.3343/alm.2015.35.1.41 Wolf, 2015, Gene therapy for neurologic manifestations of mucopolysaccharidoses, Expert Opin. Drug Deliv., 12, 283, 10.1517/17425247.2015.966682 Ahmed, 2014, Neurocognitive and neuropsychiatric phenotypes associated with the mutation L238Q of the alpha-l-iduronidase gene in Hurler-Scheie syndrome, Mol. Genet. Metab., 111, 123, 10.1016/j.ymgme.2013.11.014 Leroux, 2014, Hurler syndrome: early diagnosis and treatment, Arch. Pediatr., 21, 501, 10.1016/j.arcped.2014.02.013 Tatapudi, 2011, Mucopolysaccharidosis type I Hurler-Scheie syndrome: a rare case report, Contemp. Clin. Dent., 2, 66, 10.4103/0976-237X.79287 Prommajan, 2011, A novel p.E276K IDUA mutation decreasing alpha-l-iduronidase activity causes mucopolysaccharidosis type I, Mol. Vis., 17, 456 Bremer, 2011, A novel mucopolysaccharidosis type I associated splice site mutation and IDUA splice variants, Mol. Genet. Metab., 104, 289, 10.1016/j.ymgme.2011.07.012 Scott, 1992, A common mutation for mucopolysaccharidosis type I associated with a severe Hurler syndrome phenotype, Hum. Mutat., 1, 103, 10.1002/humu.1380010204 Scott, 1992, Alpha-l-iduronidase mutations (Q70X and P533R) associate with a severe Hurler phenotype, Hum. Mutat., 1, 333, 10.1002/humu.1380010412 Pereira, 2008, Mutational and oxidative stress analysis in patients with mucopolysaccharidosis type I undergoing enzyme replacement therapy, Clin. Chim. Acta, 387, 75, 10.1016/j.cca.2007.09.008 Scott, 1995, Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications, Hum. Mutat., 6, 288, 10.1002/humu.1380060403 Bertola, 2011, IDUA mutational profiling of a cohort of 102 European patients with mucopolysaccharidosis type I: identification and characterization of 35 novel alpha-l-iduronidase (IDUA) alleles, Hum. Mutat., 32, E2189, 10.1002/humu.21479 Chkioua, 2011, Mucopolysaccharidosis type I: molecular characteristics of two novel alpha-l-iduronidase mutations in Tunisian patients, Diagn. Pathol., 6, 47, 10.1186/1746-1596-6-47 Beck, 2014, The natural history of MPS I: global perspectives from the MPS I Registry, Genet. Med., 16, 759, 10.1038/gim.2014.25 Gunn, 2014, Long-term nonsense suppression therapy moderates MPS I-H disease progression, Mol. Genet. Metab., 111, 374, 10.1016/j.ymgme.2013.12.007 Kingma, 2013, An algorithm to predict phenotypic severity in mucopolysaccharidosis type I in the first month of life, Orphanet J. Rare Dis., 8, 99, 10.1186/1750-1172-8-99 de Ru, 2012, Capturing phenotypic heterogeneity in MPS I: results of an international consensus procedure, Orphanet J. Rare Dis., 7, 22, 10.1186/1750-1172-7-22 Beesley, 2001, Mutational analysis of 85 mucopolysaccharidosis type I families: frequency of known mutations, identifications of 17 novel mutations and in vitro expression of missense mutations, Hum. Genet., 109, 503, 10.1007/s004390100606 Cobos, 2015, Dried blood spots allow targeted screening to diagnose mucopolysaccharidosis and mucolipidosis, JIMD Rep., 15, 123 Chkioua, 2011, Molecular analysis of mucopolysaccharidosis type I in Tunisia: identification of novel mutation and eight novel polymorphisms, Diagn. Pathol., 6, 39, 10.1186/1746-1596-6-39 Chkioua, 2011, Mucopolysaccharidosis type I: molecular characteristics of two novel alpha-l-iduronidase mutations in Tunisian patients, Diagn. Pathol., 6, 47, 10.1186/1746-1596-6-47 Laradi, 2005, Mucopolysaccharidosis I: alpha-L-iduronidase mutations in three Tunisian families, J. Inherit. Metab. Dis., 28, 1019, 10.1007/s10545-005-0197-4 Kurosaki, 2016, Nonsense-mediated mRNA decay in humans at a glance, J. Cell Sci., 129, 461, 10.1242/jcs.181008 Hug, 2016, Mechanism and regulation of the nonsense-mediated decay pathway, Nucleic Acids Res., 44, 1483, 10.1093/nar/gkw010 Gotham, 2016, Synthesis and activity of a novel inhibitor of nonsense-mediated mRNA decay, Org. Biomol. Chem., 14, 1559, 10.1039/C5OB02482J Sieber, 2016, Proteomic analysis reveals branch-specific regulation of the unfolded protein response by nonsense-mediated mRNA decay, Mol. Cell. Proteomics, 10.1074/mcp.M115.054056 Miller, 2014, Nonsense-mediated decay in genetic disease: friend or foe?, Mutat. Res. Rev. Mutat. Res., 762, 52, 10.1016/j.mrrev.2014.05.001 Bhuvanagiri, 2010, NMD: RNA biology meets human genetic medicine, Biochem. J., 430, 365, 10.1042/BJ20100699